LY 344864 racemate - CAS 186543-64-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
5-HT Receptor
LY 344864 racemate is a 5-HT1F receptor agonist.
Brife Description:
5-HT1F receptor agonist
LY 344864 racemate; LY344864 racemate; LY-344864 racemate
Canonical SMILES:
1.5-HT1F receptor agonists in acute migraine treatment: a hypothesis.
Ramadan NM;Skljarevski V;Phebus LA;Johnson KW Cephalalgia. 2003 Oct;23(8):776-85.
Serotonin-1F receptor (5-HT1F) agonists may relieve acute migraine without vasoconstriction. We conducted a review of preclinical and clinical data that assessed the potential link between migraine and 5-HT1F activation. (i) A high correlation exists between the potency of various 5-HT1 receptor agonists in the guinea pig dural plasma protein extravasation assay and their 5-HT1F receptor binding affinity. (ii) 5-HT1F receptors are on the trigeminal system, and may participate in blocking migraine pain transmission through the trigeminal ganglion and nucleus caudalis. (iii) 5-HT1F receptors are located on glutamate-containing neurones and their activation might inhibit glutamate release; glutamate excess may play a role in migraine. (iv) Selective 5-HT1F receptor agonists (LY334370; LY344864) are effective in preclinical migraine models and are non-vasoconstrictive. (v) LY334370 is effective in acute migraine, and does not cause any symptoms/signs of coronary vasoconstriction. Preclinical experiments and clinical observations argue for a role of selective 5-HT1F agonists in migraine.
2.Migraine: pathophysiology, pharmacology, treatment and future trends.
Villalón CM;Centurión D;Valdivia LF;de Vries P;Saxena PR Curr Vasc Pharmacol. 2003 Mar;1(1):71-84.
Migraine treatment has evolved into the scientific arena, but it seems still controversial whether migraine is primarily a vascular or a neurological dysfunction. Irrespective of this controversy, the levels of serotonin (5-hydroxytryptamine; 5-HT), a vasoconstrictor and a central neurotransmitter, seem to decrease during migraine (with associated carotid vasodilatation) whereas an i.v. infusion of 5-HT can abort migraine. In fact, 5-HT as well as ergotamine, dihydroergotamine and other antimigraine agents invariably produce vasoconstriction in the external carotid circulation. The last decade has witnessed the advent of sumatriptan and second generation triptans (e.g. zolmitriptan, rizatriptan, naratriptan), which belong to a new class of drugs, the 5-HT1B/1D/1F receptor agonists. Compared to sumatriptan, the second-generation triptans have a higher oral bioavailability and longer plasma half-life. In line with the vascular and neurogenic theories of migraine, all triptans produce selective carotid vasoconstriction (via 5-HT1B receptors) and presynaptic inhibition of the trigeminovascular inflammatory responses implicated in migraine (via 5-HT1D/5-ht1F receptors). Moreover, selective agonists at 5-HT1D (PNU-142633) and 5-ht1F (LY344864) receptors inhibit the trigeminovascular system without producing vasoconstriction.
3.Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: effect of selective 5-HT(1F) receptor agonists and PGF(2alpha).
Cohen ML;Schenck K Br J Pharmacol. 2000 Oct;131(3):562-8.
Contractile responses to ergotamine, sumatriptan and the novel 5-HT(1F) receptor agonists, LY334370 and LY344864 were examined using the rabbit saphenous vein. Ergotamine (pEC(50)=8.7+/-0.06) was 30 fold more potent than 5-hydroxytryptamine (5-HT) (pEC(50)=7.2+/-0.13) and 300 fold more potent than sumatriptan (pEC(50)=6.0+/-0.08) in contracting the rabbit saphenous vein in vitro. The selective 5-HT(1F) receptor agonists, LY334370 or LY344864 (up to 10(-4) M), did not contract the rabbit saphenous vein. The contractile response to ergotamine in this tissue resulted from activation of both alpha(1) and 5-HT(1B/1D) receptors based on the observation that prazosin (10(-6) M), an alpha-adrenoceptor antagonist, and GR127935 (10(-8) M) a 5-HT(1B/1D) receptor antagonist, dextrally shifted the contractile response to ergotamine. In contrast, prazosin (10(-6) M) did not alter contraction to sumatriptan whereas GR127935 (10(-8) M) was a potent antagonist (-log K(B)=10.0) suggesting that sumatriptan-induced contraction of the rabbit saphenous vein was mediated only by activation of receptors similar or identical to 5-HT(1B/1D) receptors. PGF(2alpha) (3x10(-7) M) produced a modest increase (approximately 5.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related 5-HT Receptor Products

CAS 845861-49-6 2-Methyl-5-hydroxytryptamine hydrochloride

2-Methyl-5-hydroxytryptamine hydrochlori
(CAS: 845861-49-6)

2-Methyl-5-hydroxytryptamine hydrochloride is a 5-HT3 agonist (Ki = 1200 nM) and potent 5-HT6 ligand (Ki = 46 nM). It affects the gut functions including secret...

CAS 155584-74-0 VUF 10166

VUF 10166
(CAS: 155584-74-0)

VUF 10166 is a potent and competitive 5-HT3 receptor antagonist (IC50 = 0.04 and 22 nM for human 5HT3A and 5-HT3AB receptors, respectively). VUF 10166 exhibits ...

CAS 137328-52-0 LY 215840

LY 215840
(CAS: 137328-52-0)

LY 215840 is a potent antagonist of both Serotonin 2A receptor and Serotonin 7 receptor. It can reduce stimulatory effect of serotonin on aldosterone secretion ...

CAS 1220646-23-0 AVN-492

(CAS: 1220646-23-0)

AVN-492 is a novel potent and selective 5-HT6 receptor antagonist with Ki values of 91 pM and 170 nM for 5-HT6R and 5-HT2BR, respectively.

CAS 162100-15-4 SB 215505

SB 215505
(CAS: 162100-15-4)

SB 215505 is a potent and orally bioactive 5-HT2B/2C receptor antagonist (pKi = 8.3, 7.66 and 6.77 for 5-HT2B, 5-HT2C and 5-HT2A, respectively). SB 215505 incre...

CAS 864741-95-7 SB 699551 dihydrochloride

SB 699551 dihydrochloride
(CAS: 864741-95-7)

SB 699551 is a selective 5-HT5A receptor antagonist (pKi = 8.3, < 6.0, < 6.0, < 6.0, < 5.5 and < 5.5 for 5-ht5a, 5-HT1B/D, 5-HT2A, 5-HT2C, 5-HT1A and 5-HT7 rece...

CAS 179756-58-2 Eptapirone

(CAS: 179756-58-2)

Eptapirone, also known as F11440, is a potent agonist of the serotonin (5-HT) receptor subtype 5-HT1A (Ki = 4.8 nM in a radioligand binding assay).

CAS 740873-06-7 Naluzotan

(CAS: 740873-06-7)

Naluzotan is a selective 5-HT1A receptor partial agonist under the development of EPIX Pharmaceuticals. It is a serotonergic drug for the treatment of generaliz...

Quick Inquiry

Verification code

Featured Items